UID,Searchword,API,URL,Title,Summary,Article,Title_Sentiment,Title_Positive,Title_Neutral,Title_Negative,Article_Sentiment,Article_Positive,Article_Neutral,Article_Negative,Verified,Language,Topics,Date,Load_Date,Source
10711,Euroclear,Twitter API,Twitter,Watchdog report finds top banks fall short on acting to protect democracy #AAA Websites Euroclear Fintech https://t.co/5B1L4R1uB8 #regtech,nan,Watchdog report finds top banks fall short on acting to protect democracy #AAA Websites Euroclear Fintech https://t.co/5B1L4R1uB8 #regtech,negative,0.02,0.2,0.78,negative,0.02,0.2,0.78,True,English,"['Watchdog report', 'top banks', 'democracy', 'Fintech', 'B1L4R1uB8', 'regtech', 'Watchdog report', 'top banks', 'democracy', 'Fintech', 'B1L4R1uB8', 'regtech']",2022-09-29,2022-10-02,Unknown
10712,Euroclear,Twitter API,Twitter,@RandyVegetables @NiceisRich Yes  of course. They had connections to European &amp; US stock exchanges via Euroclear  C… https://t.co/57iCW06Kp0,nan,@RandyVegetables @NiceisRich Yes  of course. They had connections to European &amp; US stock exchanges via Euroclear  C… https://t.co/57iCW06Kp0,neutral,0.02,0.97,0.02,neutral,0.02,0.97,0.02,True,English,"['US stock exchanges', 'RandyVegetables', 'NiceisRich', 'course', 'connections', 'European', 'Euroclear', '57iCW06Kp0', 'US stock exchanges', 'RandyVegetables', 'NiceisRich', 'course', 'connections', 'European', 'Euroclear', '57iCW06Kp0']",2022-09-29,2022-10-02,Unknown
10713,Euroclear,Twitter API,Twitter,@RandyVegetables @NiceisRich St.Petersburg stock exchange still operate but MOEX does not (due to Euroclear and Clearstream blockade).,nan,@RandyVegetables @NiceisRich St.Petersburg stock exchange still operate but MOEX does not (due to Euroclear and Clearstream blockade).,negative,0.01,0.19,0.8,negative,0.01,0.19,0.8,True,English,"['NiceisRich St.Petersburg stock exchange', 'Clearstream blockade', 'RandyVegetables', 'MOEX', 'NiceisRich St.Petersburg stock exchange', 'Clearstream blockade', 'RandyVegetables', 'MOEX']",2022-09-29,2022-10-02,Unknown
10714,Euroclear,Twitter API,Twitter,Celsius appoints interim CEO as founder Alex Mashinsky resigns #AAA Websites Euroclear Fintech https://t.co/NwYO7XG5AI #regtech,nan,Celsius appoints interim CEO as founder Alex Mashinsky resigns #AAA Websites Euroclear Fintech https://t.co/NwYO7XG5AI #regtech,neutral,0.01,0.97,0.02,neutral,0.01,0.97,0.02,True,English,"['founder Alex Mashinsky', 'interim CEO', 'Celsius', 'Fintech', 'NwYO7XG5AI', 'regtech', 'founder Alex Mashinsky', 'interim CEO', 'Celsius', 'Fintech', 'NwYO7XG5AI', 'regtech']",2022-09-29,2022-10-02,Unknown
10790,Euroclear,Twitter API,Twitter,We are kicking off a new video series to introduce to you the #diversifiedforce behind Euroclear!Meet Hilda Adamu … https://t.co/ceKAnYZrVm,nan,We are kicking off a new video series to introduce to you the #diversifiedforce behind Euroclear!Meet Hilda Adamu … https://t.co/ceKAnYZrVm,neutral,0.1,0.88,0.02,neutral,0.1,0.88,0.02,True,English,"['new video series', 'Hilda Adamu', 'Euroclear', 'ceKAnYZrVm', 'new video series', 'Hilda Adamu', 'Euroclear', 'ceKAnYZrVm']",2022-09-30,2022-10-02,Unknown
10791,Euroclear,Twitter API,Twitter,Can a credit card teach entrepreneurs how to run a business? #AAA Websites Euroclear Fintech https://t.co/2S11G7hOxw #regtech,nan,Can a credit card teach entrepreneurs how to run a business? #AAA Websites Euroclear Fintech https://t.co/2S11G7hOxw #regtech,neutral,0.04,0.94,0.02,neutral,0.04,0.94,0.02,True,English,"['credit card', 'entrepreneurs', 'business', 'Fintech', 'S11G7hOxw', 'regtech', 'credit card', 'entrepreneurs', 'business', 'Fintech', 'S11G7hOxw', 'regtech']",2022-09-30,2022-10-02,Unknown
10792,Euroclear,Twitter API,Twitter,Embedded banking with Metro AG and Vodeno #AAA Websites Euroclear Fintech https://t.co/z0oahBZLFG #regtech,nan,Embedded banking with Metro AG and Vodeno #AAA Websites Euroclear Fintech https://t.co/z0oahBZLFG #regtech,neutral,0.01,0.98,0.01,neutral,0.01,0.98,0.01,True,English,"['Embedded banking', 'Metro AG', 'Vodeno', 'Fintech', 'z0oahBZLFG', 'regtech', 'Embedded banking', 'Metro AG', 'Vodeno', 'Fintech', 'z0oahBZLFG', 'regtech']",2022-09-30,2022-10-02,Unknown
10872,Euroclear,NewsApi.org,https://ca.sports.yahoo.com/news/merger-between-evli-plc-eab-063000140.html,The merger between Evli Plc and EAB Group Plc and Evli Plc’s share capital increase have been registered with the Trade Register,EVLI PLC STOCK EXCHANGE RELEASE OCTOBER 1  2022 AT 9:30 A.M. (EET/EEST) NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES  OR IN ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW. THE MERGER BETWEEN EVLI PLC AND EAB GROUP…,Evli PlcEVLI PLC STOCK EXCHANGE RELEASE OCTOBER 1  2022 AT 9:30 A.M. (EET/EEST)NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES  OR IN ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW.THE MERGER BETWEEN EVLI PLC AND EAB GROUP PLC AND EVLI PLC’S SHARE CAPITAL INCREASE HAVE BEEN REGISTERED WITH THE TRADE REGISTEREvli Plc (“Evli”) announces that the merger of EAB Group Plc (“EAB”) into Evli (the “Merger”) has been registered today  October 1  2022  with the Finnish Trade Register maintained by the Finnish Patent and Registration Office (the “Finnish Trade Register”). As a result of the completion of the Merger  EAB has dissolved.The shareholders of EAB will receive as merger consideration 0.172725 new series B shares in Evli for each share they own in EAB (the “Merger Consideration Shares”) and a cash consideration for a total amount of EUR three (3) million  which shall be equally distributed between the total of 13 812 395 EAB shares that were outstanding on the last trading day before the completion date of the Merger. The cash consideration thus amounts to EUR 0.217196 per share. The shareholders of EAB will receive in total 2 385 745 new B shares in Evli as merger consideration.Evli’s share capital has been increased by EUR 30 000 000 in connection with the registration of the completion of the Merger. The Merger Consideration Shares and the increase in share capital have been registered with the Finnish Trade Register today on October 1  2022.Due to the Merger Consideration Shares issued to the EAB shareholders as merger consideration and the increase in share capital in connection with the completion of the Merger  the total amount of Evli’s shares is 26 275 302  from which series B shares are 11 790 154 and the share capital is EUR 53 745 459.66.The Merger Consideration Shares will be registered in the book-entry accounts of EAB shareholders according to the policies of Euroclear Finland Oy on or about October 3  2022 and admitted to trading on the official list of Nasdaq Helsinki Ltd (“Nasdaq Helsinki”) with the trading code EVLI (ISIN code FI4000513437). The trading with the Merger Consideration Shares will begin on or about October 3  2022.Story continuesThe Merger Consideration Shares and the cash consideration shall be distributed automatically  and no actions are required from the shareholders of EAB in relation thereto. The cash portion of the merger consideration will be paid into the bank accounts connected to the book-entry accounts of the shareholders on or about October 3  2022.In case the number of shares in Evli received by a shareholder of EAB as Merger Consideration Shares is a fractional number  the fractions shall be rounded down to the nearest whole number  and fractional entitlements shall be aggregated and sold in public trading on Nasdaq Helsinki for the benefit of the shareholders of EAB entitled to such fractions. The proceeds received from the sale of the fractions will be paid to the bank accounts connected to the book entry accounts of the shareholders on or about October 5  2022.EVLI PLCBoard of DirectorsFURTHER INFORMATION:Maunu Lehtimäki  CEO  Evli Plc  tel. +358 50 553 3000  maunu.lehtimaki@evli.comRequests for interviews via the company’s communications: Mikaela Herrala  Head of Marketing  Communications and IR  Evli Plc  tel. +358 50 544 5740  mikaela.herrala@evli.comEvli in briefWe see wealth as an engine to drive progress. We draw on our heritage  broad expertise and Nordic values to grow and manage wealth for institutions  corporations and private persons in a responsible way.We are the leading asset manager in Finland* offering a broad range of services including mutual funds  asset management and capital markets services  alternative investment products  equity research  share plan design and administration as well as Corporate Finance services. Responsible investing is integrated in every investment decision and our expertise is widely acknowledged by our clients. Evli has Finland’s best expertise in responsible investment.**Evli Group employs around 250 professionals and Evli has a total of EUR 14.5 billion in client assets under management (net 6/2022). Evli Plc’s class B shares are listed on the official list of Nasdaq Helsinki Ltd.*Kantar Prospera External Asset Management Finland 2015  2016  2017  2018  2019  2021  Kantar Prospera Private Banking 2019  2020 Finland**SFR Scandinavian Financial Research Institutional Investment Services Finland 2021Distribution: Nasdaq Helsinki  main media  www.evli.comIMPORTANT NOTICEThis release is not an offer of shares in the United States and it is not intended for distribution in or into the United States or in any other jurisdiction in which such distribution would be prohibited by applicable law. The shares in the combined company will not be registered under the U.S. Securities Act of 1933 (the “Securities Act”)  and may not be offered  sold or delivered within or into the United States  except pursuant to an applicable exemption of  or in a transaction not subject to  the Securities Act.This release does not constitute an offer of or an invitation by or on behalf of Evli or any other person  to purchase any securities.This release includes ‘forward-looking statements’ that are based on present plans  estimates  projections and expectations and are not guarantees of the combined company’s future performance. They are based on certain expectations and assumptions  which  even though they seem to be reasonable at present  may turn out to be incorrect. The shareholders of Evli should not rely on these forward-looking statements. Numerous factors may cause the actual results of operations or financial condition of the combined company to differ materially from those expressed or implied in the forward-looking statements. Neither Evli nor any of its affiliates  advisors or representatives or any other person undertakes any obligation to review or confirm or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise after the date of this release.,neutral,0.01,0.94,0.05,mixed,0.41,0.25,0.34,True,English,"['share capital increase', 'EAB Group Plc', 'Evli Plc', 'Trade Register', 'merger', 'SFR Scandinavian Financial Research Institutional Investment Services Finland', 'Kantar Prospera External Asset Management Finland', 'EVLI PLC STOCK EXCHANGE RELEASE OCTOBER', 'Kantar Prospera Private Banking', 'U.S. Securities Act', '0.172725 new series B shares', 'The Merger Consideration Shares', 'MERGER BETWEEN EVLI PLC', 'alternative investment products', 'Corporate Finance services', 'leading asset manager', '2,385,745 new B shares', 'Euroclear Finland Oy', 'capital markets services', 'Maunu Lehtimäki', 'class B shares', 'Finnish Trade Register', 'book entry accounts', 'last trading day', 'nearest whole number', 'share plan design', 'Nasdaq Helsinki Ltd', 'EVLI PLC Board', 'EAB GROUP PLC', 'equity research', 'SHARE CAPITAL INCREASE', 'investment decision', 'responsible investment', 'private persons', 'Finnish Patent', 'cash consideration', 'Evli Group', '13,812,395 EAB shares', 'book-entry accounts', 'bank accounts', 'UNITED STATES', 'OTHER JURISDICTION', 'APPLICABLE LAW', 'official list', 'trading code', 'ISIN code', 'cash portion', 'fractional number', 'fractional entitlements', 'public trading', 'FURTHER INFORMATION', 'Nordic values', 'responsible way', 'broad range', 'mutual funds', 'Responsible investing', 'client assets', 'main media', 'IMPORTANT NOTICE', 'applicable exemption', 'broad expertise', 'best expertise', 'Registration Office', 'combined company', 'total amount', 'completion date', 'SUCH DISTRIBUTION', 'Mikaela Herrala', 'EAB shareholders', '9:30 A', 'EET', 'EEST', 'result', 'connection', 'policies', 'Story', 'actions', 'relation', 'case', 'benefit', 'proceeds', 'sale', 'Directors', 'CEO', 'tel', 'lehtimaki', 'Requests', 'interviews', 'communications', 'Head', 'Marketing', 'brief', 'wealth', 'engine', 'progress', 'heritage', 'institutions', 'corporations', 'administration', 'clients', '250 professionals', 'offer']",2022-10-01,2022-10-02,ca.sports.yahoo.com
10873,Euroclear,Twitter API,Twitter,Some Clover merchants suffering 'intermittent issues' #AAA Websites Euroclear Fintech https://t.co/ds8t6EVoh2 #regtech,nan,Some Clover merchants suffering 'intermittent issues' #AAA Websites Euroclear Fintech https://t.co/ds8t6EVoh2 #regtech,negative,0.01,0.1,0.89,negative,0.01,0.1,0.89,True,English,"['Clover merchants', 'intermittent issues', 'Fintech', 'ds8t6EVoh2', 'regtech', 'Clover merchants', 'intermittent issues', 'Fintech', 'ds8t6EVoh2', 'regtech']",2022-10-01,2022-10-02,Unknown
10874,Euroclear,Twitter API,Twitter,Why Silicon Valley Bank is betting on buy nowithpay later for businesses #AAA Websites Euroclear Fintech https://t.co/m6196UXHgN #regtech,nan,Why Silicon Valley Bank is betting on buy nowithpay later for businesses #AAA Websites Euroclear Fintech https://t.co/m6196UXHgN #regtech,neutral,0.03,0.95,0.03,neutral,0.03,0.95,0.03,True,English,"['Silicon Valley Bank', 'businesses', 'Fintech', 'm6196UXHgN', 'regtech', 'Silicon Valley Bank', 'businesses', 'Fintech', 'm6196UXHgN', 'regtech']",2022-10-01,2022-10-02,Unknown
10881,EuroNext,Twitter API,Twitter,@annettedittert Here’s an example of “levelling up” - for Euronext Paris. https://t.co/OjagvW4hq9,nan,@annettedittert Here’s an example of “levelling up” - for Euronext Paris. https://t.co/OjagvW4hq9,neutral,0.02,0.97,0.02,neutral,0.02,0.97,0.02,True,English,"['Euronext Paris', 'annettedittert', 'example', 'OjagvW4hq9', 'Euronext Paris', 'annettedittert', 'example', 'OjagvW4hq9']",2022-10-01,2022-10-02,Unknown
10882,EuroNext,Twitter API,Twitter,@SheeneeXXI @atari @AtariX @GameStop @euronext @wallstreetbets It means Wade can buy more stock before the offer op… https://t.co/jpCOzsQ0bP,nan,@SheeneeXXI @atari @AtariX @GameStop @euronext @wallstreetbets It means Wade can buy more stock before the offer op… https://t.co/jpCOzsQ0bP,neutral,0.03,0.95,0.02,neutral,0.03,0.95,0.02,True,English,"['SheeneeXXI', 'atari', 'GameStop', 'euronext', 'wallstreetbets', 'Wade', 'stock', 'offer', 'jpCOzsQ0bP', 'SheeneeXXI', 'atari', 'GameStop', 'euronext', 'wallstreetbets', 'Wade', 'stock', 'offer', 'jpCOzsQ0bP']",2022-10-01,2022-10-02,Unknown
10888,Euroclear,Twitter API,Twitter,@C_M_101 Well I just hope Clearnet and Euroclear are ready this time to intercede and help the other banks delevera… https://t.co/yZpySV9vdu,nan,@C_M_101 Well I just hope Clearnet and Euroclear are ready this time to intercede and help the other banks delevera… https://t.co/yZpySV9vdu,positive,0.92,0.06,0.02,positive,0.92,0.06,0.02,True,English,"['other banks', 'Clearnet', 'Euroclear', 'yZpySV9vdu', 'other banks', 'Clearnet', 'Euroclear', 'yZpySV9vdu']",2022-10-02,2022-10-02,Unknown
10889,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2022/10/01/2526404/0/en/Nyrstar-NV-FSMA-final-investigation-report.html,Nyrstar NV: FSMA final investigation report,Regulated Information Nyrstar NV: FSMA final investigation report  1 October 2022 at 23:45 CET  Nyrstar NV confirms that on 30 September 2022  the......,English DutchRegulated InformationNyrstar NV: FSMA final investigation report1 October 2022 at 23:45 CETNyrstar NV confirms that on 30 September 2022  the Management Committee of the FSMA notified it of the grievances and provided it with the auditor's final investigation report. The company is studying that notification and report together with its advisers  and is considering necessary steps. The company believes that it has at all times disclosed the required information in accordance with the relevant financial regulations and laws  and will defend that position in due course. It continues to cooperate fully with the FSMA's investigation and will  if applicable  also cooperate with any criminal investigation.About Nyrstar NVThe Company is incorporated in Belgium and listed on Euronext Brussels under the symbol NYR. For further information please visit the Nyrstar NV website: www.nyrstarnv.beFor further information contact:Anthony Simms - Head of External Affairs & Legal anthony.simms@nyrstar.comAttachment,neutral,0.03,0.5,0.47,negative,0.03,0.4,0.57,True,English,"['FSMA final investigation report', 'Nyrstar NV', 'English Dutch Regulated Information', 'FSMA final investigation report', 'relevant financial regulations', 'Nyrstar NV website', 'criminal investigation', 'Management Committee', 'necessary steps', 'due course', 'Euronext Brussels', 'External Affairs', 'Legal anthony', 'Anthony Simms', '1 October', '23:45 CET', '30 September', 'grievances', 'auditor', 'company', 'notification', 'advisers', 'times', 'accordance', 'laws', 'position', 'The', 'Belgium', 'symbol', 'nyrstarnv', 'Head', 'Attachment']",2022-10-01,2022-10-02,globenewswire.com
10890,EuroNext,Bing API,https://ca.finance.yahoo.com/news/cellectis-appoints-mark-frattini-m-202300289.html,Cellectis Appoints Mark Frattini  M.D.  Ph.D. as Chief Medical Officer,Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS)  a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies  announced today the appointment of Mark Frattini ,"Cellectis Inc.NEW YORK  Sept. 28  2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS)  a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies  announced today the appointment of Mark Frattini  M.D.  Ph.D.  as Chief Medical Officer  effective immediately.Dr. Frattini has over 20 years of experience in the field of hematological malignancies and joined Cellectis in August 2020 as Senior Vice President of Clinical Sciences. Mark has been responsible for Cellectis’ clinical leadership including the clinical development strategy of the Company’s current immune-oncology UCART product candidates. He has also been serving as a core member of the senior clinical team and has been managing a team of physicians and clinical scientists. As Chief Medical Officer  Dr. Frattini will oversee clinical research and development for Cellectis’ UCART clinical trial programs. He will remain based in Cellectis’ New York office and is joining the Company’s executive committee.“Mark already had an impressive track record before joining Cellectis. He has continued to lead our clinical teams successfully over the last two years and I am thrilled to continue working with him in this expanded role. We are confident that his extensive experience in clinical development within hematology and oncology along with his strong leadership capabilities are invaluable as we advance our pipeline of next-generation CAR T-cell therapies ” said André Choulika  Ph.D.  Chief Executive Officer at Cellectis.“I am eager to step into the role of Chief Medical Officer and I’m delighted to continue working alongside the Cellectis team as we focus our efforts on advancing our clinical pipeline “ said Mark Frattini  M.D.  Ph.D. “I’ve always been passionate about working on the next generation of cell and gene therapies that can address the unmet medical needs of patients living with blood cancers. I look forward to helping progress our pipeline and leading the ongoing advancement of Cellectis’ clinical programs.""Story continuesPrior to joining Cellectis  Dr. Frattini was Executive Medical Director  Program Lead  Global Clinical Research & Development at Celgene/Bristol Myer Squibb and was responsible for the oversight and management of several of Celgene’s sponsored programs in the hematology therapeutic area. Before joining Celgene  Dr. Frattini spent over 16 years as a physician-scientist specializing in hematologic malignancies in academia at Memorial Sloan-Kettering Cancer Center and Columbia University where he was a member of the adult leukemia service and the Experimental Therapeutics center at both institutions. At Columbia University from 2013-2018 Mark also served as the Director of Research for Hematologic Malignancies.Dr. Frattini holds a M.D. and Ph.D. in Biochemistry and Molecular Biology from The University of Chicago and received his Internal Medicine residency and Medical Oncology fellowship training at Johns Hopkins Hospital.About CellectisCellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. Cellectis utilizes an allogeneic approach for CAR-T immunotherapies in oncology  pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients  and a platform to make therapeutic gene editing in hemopoietic stem cells for various diseases. As a clinical-stage biopharmaceutical company with over 22 years of experience and expertise in gene editing  Cellectis is developing life-changing product candidates utilizing TALEN®  its gene editing technology  and PulseAgile  its pioneering electroporation system to harness the power of the immune system in order to treat diseases with unmet medical needs. Cellectis’ headquarters are in Paris  France  with locations in New York  New York and Raleigh  North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).For more information  visit www.cellectis.com. Follow Cellectis on social media: @cellectis  LinkedIn and YouTube.For further information  please contact:Media contacts:Pascalyne Wilson  Director  Communications  +33 (0)7 76 99 14 33  media@cellectis.comMargaret Gandolfo  Senior Manager  Communications  +1 (646) 628 0300Investor Relation contact:Arthur Stril  Chief Business Officer  +1 (347) 809 5980  investors@cellectis.comAshley R. Robinson  LifeSci Advisors  +1 617 430 7577Forward-looking StatementsThis press release contains “forward-looking” statements within the meaning of applicable securities laws  including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as “anticipate ” “believe ” “intend”  “expect ” “plan ” “scheduled ” “could ” “may” and “will ” or the negative of these and similar expressions. These forward-looking statements  which are based on our management’s current expectations and assumptions and on information currently available to management. Forward-looking statements include statements about the advancement of development of our UCART product candidates pipeline  the potential of our product candidate and the sufficiency of cash to fund operation. These forward-looking statements are made in light of information currently available to us and are subject to numerous risks and uncertainties  including with respect to the numerous risks associated with biopharmaceutical product candidate development. With respect to our cash runway  our operating plans  including product development plans  may change as a result of various factors  including factors currently unknown to us. Furthermore  many other important factors  including those described in our Annual Report on Form 20-F and the financial report (including the management report) for the year ended December 31  2021 and subsequent filings Cellectis makes with the Securities Exchange Commission from time to time  as well as other known and unknown risks and uncertainties may adversely affect such forward-looking statements and cause our actual results  performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Except as required by law  we assume no obligation to update these forward-looking statements publicly  or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements  even if new information becomes available in the future.Attachment",neutral,0.01,0.98,0.01,positive,0.74,0.22,0.03,True,English,"['Chief Medical Officer', 'Mark Frattini', 'M.D.', 'Ph.D.', 'Cellectis', 'Private Securities Litigation Reform Act', 'current immune-oncology UCART product candidates', 'Cellectis’ UCART clinical trial programs', 'Memorial Sloan-Kettering Cancer Center', 'next-generation CAR T-cell therapies', 'Medical Oncology fellowship training', 'life-changing product candidates', 'Cellectis’ New York office', 'applicable securities laws', 'Experimental Therapeutics center', 'Chief Medical Officer', 'unmet medical needs', 'impressive track record', 'strong leadership capabilities', 'Celgene/Bristol Myer Squibb', 'adult leukemia service', 'Internal Medicine residency', 'Johns Hopkins Hospital', 'hemopoietic stem cells', 'Investor Relation contact', 'Chief Business Officer', 'Ashley R. Robinson', 'Senior Vice President', 'Chief Executive Officer', 'pioneering electroporation system', 'pioneering gene-editing platform', 'clinical-stage biotechnology company', 'clinical-stage biopharmaceutical company', 'Nasdaq Global Market', 'Global Clinical Research', 'gene editing technology', 'last two years', 'hematology therapeutic area', 'Executive Medical Director', 'clinical development strategy', 'senior clinical team', 'Cellectis’ clinical leadership', 'Cellectis’ clinical programs', 'current expectations', 'CAR T-cells', 'gene therapies', 'Clinical Sciences', 'clinical scientists', 'executive committee', 'clinical teams', 'therapeutic gene', 'Senior Manager', 'cancer patients', 'immune system', 'GLOBE NEWSWIRE', 'Euronext Growth', 'M.D.', 'Ph.D.', 'Dr. Frattini', 'hematological malignancies', 'André Choulika', 'clinical pipeline', 'next generation', 'blood cancers', 'ongoing advancement', 'Program Lead', 'hematologic malignancies', 'Columbia University', 'Molecular Biology', 'The University', 'allogeneic approach', 'CAR-T immunotherapies', 'North Carolina', 'social media', 'Media contacts', 'Pascalyne Wilson', 'Margaret Gandolfo', 'Arthur Stril', 'LifeSci Advisors', 'Forward-looking Statements', 'press release', 'forward-looking” statements', 'similar expressions', 'life-saving cell', 'Cellectis Inc.', 'Cellectis team', 'Cellectis’ headquarters', 'core member', 'various diseases', 'Mark Frattini', 'extensive experience', '20 years', '16 years', '22 years', 'ALCLS', 'CLLS', 'appointment', 'field', 'August', 'physicians', 'expanded', 'role', 'efforts', 'Story', 'oversight', 'management', 'physician-scientist', 'academia', 'institutions', 'Biochemistry', 'Chicago', 'concept', 'shelf', 'expertise', 'TALEN®', 'PulseAgile', 'power', 'order', 'Paris', 'France', 'locations', 'Raleigh', 'information', 'LinkedIn', 'YouTube', 'Communications', 'investors', 'meaning', 'words', 'believe', 'plan', 'assumptions', '7']",2022-09-28,2022-10-02,ca.finance.yahoo.com
10891,EuroNext,Bing API,https://www.defenseworld.net/2022/10/02/invesco-sp-500-equal-weight-etf-nysearcarsp-reaches-new-12-month-low-at-127-12.html,Invesco S&P 500 Equal Weight ETF (NYSEARCA:RSP) Reaches New 12-Month Low at $127.12,Invesco S&P 500 Equal Weight ETF (NYSEARCA:RSP – Get Rating)’s stock price reached a new 52-week low during trading on Friday . The company traded as low as $127.12 and last traded at $127.12  with a volume of 80148 shares trading hands.,Invesco S&P 500 Equal Weight ETF (NYSEARCA:RSP – Get Rating)’s stock price reached a new 52-week low during trading on Friday . The company traded as low as $127.12 and last traded at $127.12  with a volume of 80148 shares trading hands. The stock had previously closed at $128.68.Invesco S&P 500 Equal Weight ETF Price PerformanceThe stock’s 50-day moving average price is $142.28 and its 200 day moving average price is $144.77.Get Invesco S&P 500 Equal Weight ETF alerts:Hedge Funds Weigh In On Invesco S&P 500 Equal Weight ETFA number of institutional investors have recently modified their holdings of RSP. Truist Financial Corp raised its position in shares of Invesco S&P 500 Equal Weight ETF by 45.2% in the first quarter. Truist Financial Corp now owns 4 694 094 shares of the company’s stock valued at $740 306 000 after purchasing an additional 1 461 561 shares during the period. Lbmc Investment Advisors LLC increased its position in Invesco S&P 500 Equal Weight ETF by 34 947.1% during the fourth quarter. Lbmc Investment Advisors LLC now owns 1 419 760 shares of the company’s stock worth $231 066 000 after acquiring an additional 1 415 709 shares during the period. US Bancorp DE increased its position in Invesco S&P 500 Equal Weight ETF by 2 770.6% during the first quarter. US Bancorp DE now owns 1 435 336 shares of the company’s stock worth $226 366 000 after acquiring an additional 1 385 335 shares during the period. Choate Investment Advisors increased its position in Invesco S&P 500 Equal Weight ETF by 72.2% during the first quarter. Choate Investment Advisors now owns 3 116 643 shares of the company’s stock worth $491 526 000 after acquiring an additional 1 306 888 shares during the period. Finally  Goldman Sachs Group Inc. increased its position in Invesco S&P 500 Equal Weight ETF by 22.2% during the first quarter. Goldman Sachs Group Inc. now owns 5 435 700 shares of the company’s stock worth $857 264 000 after acquiring an additional 986 490 shares during the period.About Invesco S&P 500 Equal Weight ETFGuggenheim S&P 500 Equal Weight ETF  formerly Rydex S&P 500 Equal Weight ETF  seeks to replicate as closely as possible  the daily performance of the S&P 500 Equal Weight Index (the Index). The Index is a capitalization-weighted index covering 500 industrial  utility  transportation and financial companies of the United States markets (mostly NYSE Euronext issues).Featured ArticlesReceive News & Ratings for Invesco S&P 500 Equal Weight ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invesco S&P 500 Equal Weight ETF and related companies with MarketBeat.com's FREE daily email newsletter.,neutral,0.01,0.95,0.04,neutral,0.02,0.94,0.04,True,English,"['Invesco S&P 500 Equal Weight ETF', 'NYSEARCA:RSP', 'New 12', 'Month', 'Invesco S&P 500 Equal Weight ETF Price Performance', 'Invesco S&P 500 Equal Weight ETF alerts', 'Guggenheim S&P 500 Equal Weight ETF', 'Rydex S&P 500 Equal Weight ETF', 'S&P 500 Equal Weight Index', '50-day moving average price', '200 day moving average price', 'Goldman Sachs Group Inc.', 'Lbmc Investment Advisors LLC', 'FREE daily email newsletter', 'Choate Investment Advisors', 'US Bancorp DE', 'United States markets', 'NYSE Euronext issues', 'concise daily summary', 'Truist Financial Corp', 'daily performance', '80148 shares trading hands', 'stock price', 'email address', 'financial companies', 'The Index', 'capitalization-weighted index', 'Get Rating', 'new 52-week', 'Hedge Funds', 'institutional investors', 'first quarter', 'fourth quarter', 'Featured Articles', 'related companies', 'MarketBeat.com', 'additional 1,461,561 shares', 'additional 1,415,709 shares', 'additional 1,385,335 shares', 'additional 1,306,888 shares', 'additional 986,490 shares', 'NYSEARCA:RSP', 'latest news', ""analysts' ratings"", '4,694,094 shares', '1,419,760 shares', '1,435,336 shares', '3,116,643 shares', '5,435,700 shares', 'Friday', 'company', 'volume', 'number', 'holdings', 'position', 'period', 'transportation']",2022-10-02,2022-10-02,defenseworld.net
